Clinical Trial to Evaluate the Efficacy and Safety of CKD-386

Phase 3CompletedNCT04312698

Chong Kun Dang Pharmaceutical100 enrolled

Overview

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

100

Conditions

Dyslipidemia Patients With Hypertension

Interventions

D013, D326, D337DRUG

Experimental: Group 1 Patients assigned to this group are treated with D013, D326, D337

placebo of D013, D326, D337DRUG

Placebo Comparator: Group 1 Patients assigned to this group are treated with D326, D337, placebo of D013

D013, placebo of D326, placebo of D337DRUG

Placebo Comparator: Group 2 Patients assigned to this group are treated with D013, placebo of D326, placebo of D337

Eligibility

Sex: ALLMin age: 19 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Subjects are diagnosed with Dyslipidemia Patients with Hypertension or are being administered anti-hypertension and anti-hypertension drugs after diagnosis. 2. Subjects who agreed to participate in this clinical trial voluntarily. Exclusion Criteria: 1. Subjects who were satisfied specific blood pressure levels that measured at screening period. 2. Subjects who were satisfied specific lipid levels that measured at screening period. 3. Subjects who cannot participate in a clinical trial based on the PI's judgment.

Locations (1)

Yonsei University Medical Center Severance Hospital

Seoul, South Korea

Outcomes

Primary Outcomes

Change rate from baseline in LDL-C

Compare experimental group 1 with comparator group 1

Time frame: 8 weeks after drug administrations

Change from baseline in MSSBP

Compare experimental group 1 with comparator group 2

Time frame: 8 weeks after drug administrations

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.